# Drug-screening in AML at Relapse for Targeted Treatment

> **NCT05732688** · NA · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 30 (actual)

## Conditions studied

- AML

## Interventions

- **DIAGNOSTIC_TEST:** Image-based ex-vivo drug screening platform (pharmacoscopy)

## Key facts

- **NCT ID:** NCT05732688
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2024-04-01
- **Final completion:** 2024-07-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05732688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05732688, "Drug-screening in AML at Relapse for Targeted Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05732688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*